8-10 years ahead' of field in oral delivery, senior execs say Novo is becoming a GLP-1 company

16 May 2018
2019_biotech_test_vial_discovery_big

At a media event at Novo Nordisk (NOV: N) headquarters in Copenhagen, the Danish diabetes giant provided insights into its clinical and commercial strategies on Wednesday.

While chief executive Lars Fruergaard Jørgensen said the firm was “more and more becoming a GLP-1 based company," chief scientific officer Mads Krogsgaard Thomsen said Novo was “maybe 8-10 years ahead of competition in oral GLP-1.”

The firm has suffered from declining sales in parts of its key revenue-generating insulin portfolio recently, but has a promising story to tell about the potential for new forms of diabetes management, including the first oral biologic, as well as the potential to play in the growing market for obesity therapies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology